ABSTRACT Background: The Home Office has recently published estimates which, for the first time, provide a ''robust national estimate'' of the number of problematic drug users in England. The 2004/05 and 2005/06 estimates are the highest estimates ever produced for England and coincide with the highest ever government annual expenditure on combating illicit drug use. Methods and Results: Review of a range of data sources that indicate a downward trend in problematic drug use in recent years. Conclusions: The validity of the estimates is important for drug policy, and the paper considers the implications of both increasing and decreasing levels of problematic drug use.
The Home Office has recently published estimates of the number of problematic drug users (PDU) in England for 2004/05 1 and 2005/06. 2 The first study report states that the method used ''provides for the first time a robust national estimate of this important target group''. Previous estimates are said to be less robust because they ''had very wide confidence intervals within which the true estimate might lie''. The 2004/05 and 2005/06 estimates are the highest estimates ever produced for England and coincide with the highest ever annual UK government's direct expenditure on combating illicit drug use of £1.48 billion in 2005/06. 3 However, robustness is not just a matter of confidence intervals but of the validity of the data and methods that underlie the estimates. The implication of the 2004/05 and 2005/06 estimates is that PDU is at an all time high. Elsewhere, the authors of these estimates discuss a scenario in which PDU in the UK may continue to increase to over 1 million by 2025. 4 However, other data sources, described below, indicate a downward trend in PDU in recent years.
The recent PDU estimates are based on two statistical techniques: the capture recapture method (CRM) and (to a lesser extent) the multiple indicator method (MIM). Both are indirect ways of estimating prevalence and rely on data on known drug users. 5 6 Indirect methods are generally used for PDU, as direct methods such as population surveys have obvious limitations for this group.
In practice, the assumptions of both methods are difficult to verify. An alternative approach to evaluating robustness is to consider the criterion validity of the estimates. Criterion-related validity includes ''any validity strategies that focus on the correlation of the measure being validated with some well-respected outside measure(s) of the same objectives or specifications''. 7 One way of assessing the criterion validity of the estimates is to compare trends in prevalence estimates and other measures of PDU. The estimates would have criterion validity if the magnitude and direction of change in PDU prevalence estimates were similar to the change in drug indicators.
National and (3) the number of hospital admissions that are due to drug abuse. 13 All three of these indicators are potentially less biased than, for example, the number of drug offences, which is more likely to be influenced by policy.
14 For the BCS, the most appropriate indicator is the level of class A drug use in the last month. There is also further evidence that PDU has declined in recent years. The Home Office's Drug Harm Index (DHI) mirrors the indicators reported here. The DHI incorporates measures of the harms that individuals and society suffer due to drugrelated crime, the health impacts arising from drug abuse and the impact of drug use and dealing on communities. This is achieved using readily available published data for each of the harms, which are then combined into a single figure time-series index. 15 In 1998, the index was calibrated at 100, increasing to 120. 17 and has stated that they have ''failed''. 18 An alternative scenario would be that the actual PDU level is significantly lower than the published estimate, which is therefore not as ''robust'' as has been claimed. A recent Swiss study reported that heroin substitution programmes with methadone or buprenorphine are associated with declining incidence of heroin use in treatment in Switzerland, 19 perhaps because the medicalisation of drug addiction has changed the image of heroin such that it is no longer seen as an attractive drug of choice for many young people. Although the authors of the Swiss study are careful to avoid claiming that there is a direct causal association, their detailed analysis is at least consistent with this hypothesis. The analysis presented here is similarly consistent, but the cultural context of drug use in the UK is very different, and further analysis is required to evaluate the impact of different prevention and treatment strategies.
